SynthesisFrontiers in pain research (Lausanne, Switzerland)2026
Evaluation of the efficacy and safety of tegileridine at different doses in patients with postoperative pain: a meta-analysis of randomized controlled trials.
Synthesis in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to comprehensively evaluate the efficacy and safety of tegileridine at different doses in patients with postoperative acute pain through a meta-analysis. Methods: A systematic literature search was conducted across six databases from their inception to 24 March 2026 to identify all randomized controlled trials (RCTs) involving tegileridine for the treatment of postoperative acute pain. Meta-analyses were performed using RevMan 5.4 software. Results: A total of four cohorts from three RCTs involving 1,011 patients were included. Compared with placebo, tegileridine significantly reduced rSPID24 and rSPID12, demonstrating superior analgesic efficacy. Compared with morphine, there was no significant difference at rSPID12; however, tegileridine exhibited significantly weaker efficacy than morphine at rSPID24. Safety analyses revealed that although the total adverse events with tegileridine were higher than with placebo, it remained comparable to that of morphine. The incidence of nausea and vomiting with tegileridine was similar to that with placebo and significantly lower than that with morphine. No significant difference was observed in the incidence of respiratory depression between tegileridine and morphine. Conclusion: This meta-analysis demonstrates that the efficacy of tegileridine was significantly superior to that of placebo, and it had a more favorable safety profile than morphine regarding nausea and vomiting, suggesting its potential as a viable alternative for postoperative acute pain. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/view/CRD420261364062/1/0], PROSPERO CRD420261364062.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.